Skip to main content
SpringerLink
Log in

Clinicopathological Features and Molecular Analysis of Primary Glioblastomas in Moroccan Patients

  • Published:
Journal of Molecular Neuroscience Aims and scope Submit manuscript

Abstract

Glioblastoma is the most frequent and most aggressive primary brain tumor. Primary and secondary glioblastomas develop through different genetic pathways. The aim of this study was to determinate the genetic and clinical features of primary glioblastoma in Moroccan patients. The blood and tumor samples were obtained from a group of 34 Moroccan patients affected with primary glioblastoma. The tumors were investigated for TP53, IDH1, and IDH2 mutations using PCR sequencing analysis. Clinicopathological data showed that the mean age at diagnosis of patients was 50.06 years, the sex ratio was 11 F/23 M, and the median of Karnofsky performance score was 60. About 18 % of patients were initially treated by total tumor resection, 41 % by subtotal, and 38 % by partial resection, but biopsy was performed for a single patient (3 %). Twenty-five patients (74 %) received radiotherapy. In addition, the median survival of the all patients was 13 months following diagnosis. There was a significant impact of higher Karnofsky performance score (KPS) (≥80) on overall survival, p-log-rank test = 0.0002, whereas other parameters did not show any significant differences. The molecular analysis revealed TP53 mutations in 3/34 (8.82 %) cases; R273H, R306X, and Q136X. However, none of the analyzed samples contained the R132-IDH1 or R172-IDH2 mutations. These results showed the absence of IDH1 mutation in primary glioblastoma, confirming that this mutation is a hallmark of secondary glioblastoma. It can be used to distinguish primary from secondary glioblastomas. We found also that higher KPS was a significantly favorable factor in patients with primary glioblastoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  • Antonelli M, Buttarelli FR, Arcella A et al (2010) Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas. J Neurooncol 99(2):209–215

    Article  PubMed  CAS  Google Scholar 

  • Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116(6):597–602

    Article  PubMed  CAS  Google Scholar 

  • Batchelor TT, Betensky RA, Esposito JM et al (2004) Age-dependent prognostic effects of genetic alterations in glioblastoma. Clin Cancer Res 10(1 Pt 1):228–233

    Article  PubMed  CAS  Google Scholar 

  • Benito R, Gil-Benso R, Quilis V et al (2010) Primary glioblastomas with and without EGFR amplification: Relationship to genetic alterations and clinicopathological features. Neuropathology 30(4):392–400

    Article  PubMed  Google Scholar 

  • Birner P, Piribauer M, Fischer I et al (2002) Prognostic relevance of p53 protein expression in glioblastoma. Oncol Rep 9(4):703–707

    PubMed  CAS  Google Scholar 

  • Bleeker FE, Atai NA, Lamba S et al (2010) The prognostic IDH1( R132) mutation is associated with reduced NADP + −dependent IDH activity in glioblastoma. Acta Neuropathol 119(4):487–494

    Article  PubMed  CAS  Google Scholar 

  • Bleeker FE, Lamba S, Leenstra S et al (2009) IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat 30(1):7–11

    Article  PubMed  CAS  Google Scholar 

  • Burton EC, Lamborn KR, Forsyth P et al (2002) Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors. Clin Cancer Res 8(1):180–187

    PubMed  CAS  Google Scholar 

  • Chen YJ, Hakin-Smith V, Teo M et al (2006) Association of mutant TP53 with alternative lengthening of telomeres and favorable prognosis in glioma. Cancer Res 66(13):6473–6476

    Article  PubMed  CAS  Google Scholar 

  • Fine HA (1994) The basis for current treatment recommendations for malignant gliomas. J Neurooncol 20(2):111–120

    Article  PubMed  CAS  Google Scholar 

  • Furnari FB, Fenton T, Bachoo RM et al (2007) Malignant astrocytic glioma: Genetics, biology, and paths to treatment. Genes Dev 21(21):2683–2710

    Article  PubMed  CAS  Google Scholar 

  • Hartmann C, Meyer J, Balss J et al (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: A study of 1,010 diffuse gliomas. Acta Neuropathol 118(4):469–474

    Article  PubMed  Google Scholar 

  • Ichimura K, Pearson DM, Kocialkowski S et al (2009) IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 11(4):341–347

    Article  PubMed  CAS  Google Scholar 

  • Kleihues P, Ohgaki H (1997) Genetics of glioma progression and the definition of primary and secondary glioblastoma. Brain Pathol 7:1131–1136

    Article  CAS  Google Scholar 

  • Krell D, Assoku M, Galloway M, Mulholland P, Tomlinson I, Bardella C (2011) Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH mutations in glioblastoma. PLoS One 6(5):e19868

    Article  PubMed  CAS  Google Scholar 

  • Krex D, Klink B, Hartmann C et al (2007) Long-term survival with glioblastoma multiforme. Brain 130(Pt 10):2596–2606

    Article  PubMed  Google Scholar 

  • Lee SH, Jo SH, Lee SM et al (2004) Role of NADP + −dependent isocitrate dehydrogenase (NADP + −ICDH) on cellular defence against oxidative injury by gamma rays. Int J Radiat Biol 80(9):635–642

    Article  PubMed  CAS  Google Scholar 

  • Louis D, Ohgaki H, Wiestler O, Cavenee W (2007) WHO classification of tumors of the nervous system. IARC, Lyon

    Google Scholar 

  • Mellai M, Piazzi A, Caldera V et al (2011) IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors. J Neurooncol 105(2):345–357

    Article  PubMed  CAS  Google Scholar 

  • Murugan AK, Bojdani E, Xing M (2010) Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer. Biochem Biophys Res Commun 393(3):555–559

    Article  PubMed  CAS  Google Scholar 

  • Narahara K, Kimura S, Kikkawa K et al (1985) Probable assignment of soluble isocitrate dehydrogenase (IDH1) to 2q33.3. Hum Genet 71(1):37–40

    Article  PubMed  CAS  Google Scholar 

  • Nayak A, Ralte AM, Sharma MC et al (2004) p53 protein alterations in adult astrocytic tumors and oligodendrogliomas. Neurol India 52(2):228–232

    PubMed  Google Scholar 

  • Nobusawa S, Watanabe T, Kleihues P, Ohgaki H (2009) IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 15(19):6002–6007

    Article  PubMed  CAS  Google Scholar 

  • Ohgaki H (2005) Genetic pathways to glioblastomas. Neuropathology 25(1):1–7

    Article  PubMed  Google Scholar 

  • Ohgaki H, Dessen P, Jourde B et al (2004) Genetic pathways to glioblastoma: A population-based study. Cancer Res 64(19):6892–6899

    Article  PubMed  CAS  Google Scholar 

  • Ohgaki H, Kleihues P (2005) Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64(6):479–489

    PubMed  CAS  Google Scholar 

  • Ohgaki H, Kleihues P (2007) Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170(5):1445–1453

    Article  PubMed  CAS  Google Scholar 

  • Ohgaki H, Kleihues P (2009) Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci 100(12):2235–2241

    Article  PubMed  CAS  Google Scholar 

  • Parsons DW, Jones S, Zhang X et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321(5897):1807–1812

    Article  PubMed  CAS  Google Scholar 

  • Petitjean A, Mathe E, Kato S et al (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: Lessons from recent developments in the IARC TP53 database. Hum Mutat 28(6):622–629

    Article  PubMed  CAS  Google Scholar 

  • Reitman ZJ, Yan H (2010) Isocitrate dehydrogenase 1 and 2 mutations in cancer: Alterations at a crossroads of cellular metabolism. J Natl Cancer Inst 102(13):932–941

    Article  PubMed  CAS  Google Scholar 

  • Rich JN, Hans C, Jones B et al (2005) Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res 65(10):4051–4058

    Article  PubMed  CAS  Google Scholar 

  • Sambrook J, Fritsch EF, Maniatis T (1989) Molecular cloning: A laboratory manual (Ed C. S. Harbor). New York: Cold Spring Harbor Laboratory

  • Sanson M, Marie Y, Paris S et al (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27(25):4150–4154

    Article  PubMed  CAS  Google Scholar 

  • Scott JN, Rewcastle NB, Brasher PM et al (1999) Which glioblastoma multiforme patient will become a long-term survivor? A population-based study. Ann Neurol 46(2):183–188

    Article  PubMed  CAS  Google Scholar 

  • Shiraishi S, Tada K, Nakamura H et al (2002) Influence of p53 mutations on prognosis of patients with glioblastoma. Cancer 95(2):249–257

    Article  PubMed  CAS  Google Scholar 

  • Sonoda Y, Kumabe T, Nakamura T et al (2009a) Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci 100(10):1996–1998

    Article  PubMed  CAS  Google Scholar 

  • Sonoda Y, Kumabe T, Watanabe M et al (2009b) Long-term survivors of glioblastoma: Clinical features and molecular analysis. Acta Neurochir (Wien) 151(11):1349–1358

    Article  Google Scholar 

  • Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: A randomised controlled multicentre phase III trial. Lancet Oncol 7(5):392–401

    Article  PubMed  CAS  Google Scholar 

  • Uno M, Oba-Shinjo SM, Silva R et al (2011) IDH1 mutations in a Brazilian series of glioblastoma. Clinics (Sao Paulo) 66(1):163–165

    Article  Google Scholar 

  • Vertosick FT, Selker RG Jr (1992) Long-term survival after the diagnosis of malignant glioma: a series of 22 patients surviving more than 4 years after diagnosis. Surg Neurol 38(5):359–363

    Article  PubMed  Google Scholar 

  • Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408(6810):307–310

    Article  PubMed  CAS  Google Scholar 

  • Watanabe K, Sato K, Biernat W et al (1997) Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res 3(4):523–530

    PubMed  CAS  Google Scholar 

  • Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H (1996) Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 6(3):217–223, discussion 223–214

    Article  PubMed  CAS  Google Scholar 

  • Watanabe T, Nobusawa S, Kleihues P, Ohgaki H (2009) IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174(4):1149–1153

    Article  PubMed  CAS  Google Scholar 

  • Weller M, Felsberg J, Hartmann C et al (2009) Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: A prospective translational study of the German Glioma Network. J Clin Oncol 27(34):5743–5750

    Article  PubMed  CAS  Google Scholar 

  • Xu X, Zhao J, Xu Z et al (2004) Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity. J Biol Chem 279(32):33946–33957

    Article  PubMed  CAS  Google Scholar 

  • Yan H, Parsons DW, Jin G et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360(8):765–773

    Article  PubMed  CAS  Google Scholar 

  • Yan W, Zhang W, You G et al (2012) Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: A report of 118 patients from China. PLoS One 7(1):e30339

    Article  PubMed  CAS  Google Scholar 

  • Zhou YX, Wang JX, Feng M, et al. (2011) Analysis of isocitrate dehydrogenase 1 mutation in 97 patients with glioma. J Mol Neurosci

Download references

Acknowledgments

We sincerely thank the neurosurgeons of CHU Ibn Rochd of Casablanca. We also thank the patients for their participation in this study.

Author information

Authors and Affiliations

  1. Laboratoire de Génétique Moléculaire Humaine, Département de la Recherche Scientifique, Institut Pasteur du Maroc, 1 Place Louis Pasteur, 20360, Casablanca, Morocco

    Omar Abidi, Houda Benrahma & Abdelhamid Barakat

  2. Service de Neurochirurgie, Centre Hospitalier Universitaire Ibn Rochd, Casablanca, Morocco

    Said Hilmani & Abdessamad El Azhari

  3. Laboratoire d’Anatomopathologie, Centre Hospitalier Universitaire Ibn Rochd, Casablanca, Morocco

    Mehdi Karkouri

  4. Centre d’Oncologie et Radiothérapie, Centre Hospitalier Universitaire Ibn Rochd, Casablanca, Morocco

    Souha Sahraoui

Authors
  1. Said Hilmani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Omar Abidi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Houda Benrahma
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mehdi Karkouri
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Souha Sahraoui
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Abdessamad El Azhari
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Abdelhamid Barakat
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Omar Abidi.

Additional information

Said Hilmani and Omar Abidi contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hilmani, S., Abidi, O., Benrahma, H. et al. Clinicopathological Features and Molecular Analysis of Primary Glioblastomas in Moroccan Patients. J Mol Neurosci 49, 567–573 (2013). https://doi.org/10.1007/s12031-012-9868-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12031-012-9868-4

Keywords

Search

Navigation